Abbott Laboratories

Recent news

• Rating change
  Citi Maintains Abbott Laboratories(ABT.US) With Buy Rating, Announces Target Price $125
  \u5e02\u573a\u8d44\u8baf · 2026/8/14
• Company notice
  ABT Networks: Huaan Securities Co., Ltd.'s Special Verification Opinion on the Placement and Utilization of Raised Funds by Prologis Technology Co., Ltd. for the 2025 Fiscal Year
  SZSI · 2026/4/10
• Rating change
  BTIG Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $134
  \u5e02\u573a\u8d44\u8baf · 2026/8/21
• J.P. Morgan Initiates Abbott Laboratories(ABT.US) With Buy Rating, Announces Target Price $120
  \u5e02\u573a\u8d44\u8baf · 2026/10/8
• Company notice
  ABT Networks: Articles of Association of Beijing Prologis Technology Co., Ltd.
  SZSI · 2026/4/10
• Barclays Maintains Abbott Laboratories(ABT.US) With Buy Rating, Cuts Target Price to $120
  \u5e02\u573a\u8d44\u8baf · 2026/10/7
• Company notice
  ABT Networks: Special Verification Report by Zhong Ruicheng Certified Public Accountants (Special General Partnership) on the Revenue Deduction Schedule of Prologis Technology Co., Ltd. for the Fiscal Year 2025
  SZSI · 2026/4/10
• Rating change
  TD Cowen Maintains Abbott Laboratories(ABT.US) With Buy Rating, Raises Target Price to $135
  \u5e02\u573a\u8d44\u8baf · 2026/8/21
• Wells Fargo Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $112
  \u5e02\u573a\u8d44\u8baf · 2026/10/5
• Rating change
  Piper Sandler Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $118
  \u5e02\u573a\u8d44\u8baf · 2026/8/26
• Company notice
  ABT Networks: Special Report by CIRC Accounting Firm (Special General Partnership) on Non-operating Fund Occupancy and Other Related Fund Transactions of Prologis Technology Co., Ltd. for the 2025 Fiscal Year
  SZSI · 2026/4/10
• Company notice
  ABT Networks: Assurance Report by Zhongrui Cheng Certified Public Accountants (Special General Partnership) on the Annual Storage and Actual Usage of Raised Funds by Beijing Prologis Technology Co., Ltd.
  SZSI · 2026/4/10
• Rating change
  TD Cowen Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $135
  \u5e02\u573a\u8d44\u8baf · 2026/9/14
• RBC Capital Initiates Abbott Laboratories(ABT.US) With Buy Rating, Announces Target Price $130
  \u5e02\u573a\u8d44\u8baf · 2026/10/3
• Rating change
  J.P. Morgan Maintains Abbott Laboratories(ABT.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/9/1
• Rating change
  Jefferies Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $135
  \u5e02\u573a\u8d44\u8baf · 2026/8/22
• Rating change
  BofA Securities Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $115
  \u5e02\u573a\u8d44\u8baf · 2026/10/2
• Rating change
  Rothschild & Co Redburn Initiates Abbott Laboratories(ABT.US) With Buy Rating, Announces Target Price $127
  \u5e02\u573a\u8d44\u8baf · 2026/10/2
• Citi Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $125
  \u5e02\u573a\u8d44\u8baf · 2026/10/5
• Rating change
  William Blair Maintains Abbott Laboratories(ABT.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/8/21
• Rating change
  Wolfe Research Upgrades Abbott Laboratories(ABT.US) to Buy Rating, Announces Target Price $130
  \u5e02\u573a\u8d44\u8baf · 2026/8/13
• Rating change
  TD Cowen Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $115
  \u5e02\u573a\u8d44\u8baf · 2026/7/29
• Rating change
  Citi Maintains Abbott Laboratories(ABT.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/8/5
• Abbott Laboratories(ABT.US) Officer Sells US$46.2 Million in Common Stock
  \u5e02\u573a\u8d44\u8baf · 2026/8/28
• Citi Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $125
  \u5e02\u573a\u8d44\u8baf · 2026/9/10

Headlines are aggregated automatically and are not independently verified or edited by our team.